CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
By B. Coiffier, É. Lepage, J. Brière, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard and 3 more. New England Journal of Medicine, 2002
3,366 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/29add147b0d850cbeca0d9db98ddac7bd4841d15
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). (2003, neutral): “Induction CR 33 (20-46) 15 (5-25) Induction CR PR 90 (82-98) 77 (66-89) Consolidation PR to CR* 10 (2-18) 22 (13-36) Overall CR 47 (33-61) 28 (16-40) Overall PR CR 90 (82-98) 77 (66-89)”
- CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. (2005, result): “These data are consistent with previous studies of rituximab.(22,33) The incidence of grade 3 or 4 neutropenia was higher during treatment with R-CVP (24%) compared with CVP (14%), but there was no difference between groups in the overall infection rate or incidence of neutropenic sepsis.”
- Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (2014, background): “In DLBCL, bulk is predictive of inferior survival in favorable-prognosis disease(124,125) but not in poorprognosis disease, probably because its influence is superseded by other factors reflecting disease burden.(126) The longest diameter of the largest involved node is included in the FL Internatio”
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma (2021, background): “** An International Prognostic Index (IPI) score indicates low (0 or 1), low–intermediate (2), high–intermediate (3), or high (4 or 5) risk of a poor outcome on the basis of a scoring system that gives one point for each of the following risk factors: age older than 60 years, 1 or more extranodal ar”
- A tumorigenic subpopulation with stem cell properties in melanomas. (2005, background): “Monoclonal antibodies against CD20 have become a standard treatment for non-Hodgkin’s lymphoma (56).”
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2019, background): “Although DLBCL is often curable, 30%-40% of patients are refractory to, or relapse after treatment with, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemoimmunotherapy, the current standard of care.(3,4) Higher treatment failure rates are observed in poor-risk subg”
- Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. (2004, neutral): “Bone marrow infiltration, involved only, % 25 (1-90) 30 (4-90) 16 (5-90)”